Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
From the U.S. FDA-approved label for Repaglinide. Full label: DailyMed.
Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
From the U.S. FDA-approved label for Repaglinide. Full label: DailyMed.
The recommended starting dose is 0.5 mg orally before each meal if HbA1c is less than 8%; and 1 or 2 mg orally before each meal if HbA1c is 8% or greater. The recommended dose range is 0.5 mg to 4 mg before meals, with a maximum daily dose of 16 mg. The patient’s dose should be doubled up to 4 mg with each meal until satisfactory glycemic control is achieved.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Repaglinide tablets are contraindicated in patients with: Concomitant use of gemfibrozil Known hypersensitivity to repaglinide or any inactive ingredients Concomitant use with gemfibrozil Known hypersensitivity to repaglinide or any inactive ingredients
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Hypoglycemia: Repaglinide may cause hypoglycemia. Skip the scheduled dose of repaglinide if a meal is skipped to reduce the risk of hypoglycemia. Reduce the dose of repaglinide if hypoglycemia occurs. Serious Cardiovascular Adverse Reactions with Concomitant NPH-insulin: Repaglinide is not indicated for use in combination with NPH-insulin. Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with repaglinide. 5.1 Hypoglycemia All glinides, including repaglinide, can cause hypoglycemia.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following serious adverse reaction is also described elsewhere in the labeling: Hypoglycemia The most common adverse reactions (5% or greater incidence) among patients treated with repaglinide were: hypoglycemia, upper respiratory infection, headache, sinusitis, arthralgia, nausea, diarrhea, and back pain. To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
76 products from 30 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Eurepa 0.5mg Tablet | Repaglinide (0.5mg) | Torrent Pharmaceuticals Ltd. | |
| Eurepa 1mg Tablet | Repaglinide (1mg) | Torrent Pharmaceuticals Ltd. | |
| Eurepa 2mg Tablet | Repaglinide (2mg) | Torrent Pharmaceuticals Ltd. | |
| Novonorm 0.5 Tablet | Repaglinide | Novartis India Ltd. | |
| Novonorm 1 Tablet | Repaglinide | Novartis India Ltd. | |
| Novonorm 2 Tablet | Repaglinide | Novartis India Ltd. | |
| Premil 0.5mg Tablet | Repaglinide (0.5mg) | Beximco Pharmaceuticals Ltd. | |
| Premil 1mg Tablet | Repaglinide (1mg) | Beximco Pharmaceuticals Ltd. | |
| Premil 2mg Tablet | Repaglinide (2mg) | Beximco Pharmaceuticals Ltd. | |
| Repanide 0.5mg Tablet | Repaglinide (0.5mg) | Quest Pharmaceuticals Pvt. Ltd. | |
| Repanide 1mg Tablet | Repaglinide (1mg) | Quest Pharmaceuticals Pvt. Ltd. | |
| Repanide 2mg Tablet | Repaglinide (2mg) | Quest Pharmaceuticals Pvt. Ltd. | |
| Benzorepa 1mg Tablet | Repaglinide (1mg) | Ranmarc Labs | strip of 10 tablets |
| Eurepa 0.5 Tablet | Repaglinide (0.5mg) | Torrent Pharmaceuticals Ltd | strip of 15 tablets |
| Eurepa 1 Tablet | Repaglinide (1mg) | Torrent Pharmaceuticals Ltd | strip of 15 tablets |
| Eurepa 2 Tablet | Repaglinide (2mg) | Torrent Pharmaceuticals Ltd | strip of 15 tablets |
| Genericart Repaglinide 1mg Tablet | Repaglinide (1mg) | Swast Aushadhi Seva Generic Medicine Store | strip of 10 tablets |
| Hirepa 0.5mg Tablet | Repaglinide (0.5mg) | Healing Pharma India Pvt Ltd | strip of 10 tablets |
| Hirepa 1mg Tablet | Repaglinide (1mg) | Healing Pharma India Pvt Ltd | strip of 10 tablets |
| Hirepa 2mg Tablet | Repaglinide (2mg) | Healing Pharma India Pvt Ltd | strip of 10 tablets |
| Lunch ON 0.5mg Tablet | Repaglinide (0.5mg) | Icon Life Sciences | strip of 10 tablets |
| Lunch ON 1mg Tablet | Repaglinide (1mg) | Illumin Pharma | strip of 10 tablets |
| Lunch ON 2mg Tablet | Repaglinide (2mg) | Icon Life Sciences | strip of 10 tablets |
| Mage 0.5mg Tablet | Repaglinide (0.5mg) | Eris Lifesciences Ltd | strip of 10 tablets |
| Mage 1mg Tablet | Repaglinide (1mg) | Eris Lifesciences Ltd | strip of 10 tablets |
| Mage 2mg Tablet | Repaglinide (2mg) | Eris Lifesciences Ltd | strip of 10 tablets |
| Novonorm 0.5mg Tablet | Repaglinide (0.5mg) | Novo Nordisk India Pvt Ltd | strip of 15 tablets |
| Novonorm 1mg Tablet | Repaglinide (1mg) | Novo Nordisk India Pvt Ltd | strip of 15 tablets |
| Novonorm 2mg Tablet | Repaglinide (2mg) | Novo Nordisk India Pvt Ltd | strip of 15 tablets |
| Page 0.5mg Tablet | Repaglinide (0.5mg) | Orchid Chemicals & Pharmaceuticals Ltd | strip of 10 tablets |
Showing 30 of 76 catalog products. Search the full catalog in the app.
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Store at 20° to 25°C (68° to 77°F). Protect from moisture. Keep bottles tightly closed.
Storage information from the U.S. FDA-approved label.
Repaglinide is recorded in the NepalDoc medicine catalog for: Type 2 DM.
For Type 2 DM: Acarbose, Glibenclamide, Gliclazide, Glimepiride, Glipizide, Metformin.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.